LCM
ARTL icon

LVM Capital Management’s Artelo Biosciences ARTL Stock Holding History

LVM Capital Management’s Portfolio ARTL Stock Details ARTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-44
Closed -$9K – 131
2021
Q3 		$9K Sell
44
-30
-41% -$7.62K ﹤0.01% 127
2021
Q2 		$24K Hold
74
– – ﹤0.01% 127
2021
Q1 		$33K Buy
+74
New +$31.6K 0.01% 125

Other funds holding ARTL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KC
Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

LVM Capital Management's ARTL Position: Q4 2021 in Review

LVM Capital Management sold out of Artelo Biosciences (ARTL) in Q4 2021, closing a stake of 44 shares — an estimated $9K sold.

LVM Capital Management first reported a position in ARTL in Q1 2021 and held it in 3 quarters. The position peaked at $33K in Q1 2021. 19 funds tracked by Wall St. Rank hold ARTL as of Q4 2021.

  • LVM Capital Management reported no remaining Artelo Biosciences position as of Q4 2021 after selling out during the quarter.
  • LVM Capital Management sold 44 Artelo Biosciences shares in Q4 2021, an estimated $9K.
  • LVM Capital Management first reported a position in Artelo Biosciences in Q1 2021 and held it in 3 quarters.
  • LVM Capital Management's Artelo Biosciences position peaked at $33K in Q1 2021.
  • 19 funds tracked by Wall St. Rank held Artelo Biosciences as of Q4 2021.

Based on LVM Capital Management's 13F filing for Q4 2021, filed 4 Jan 2022.